Persistent Asset Partners’s Pacira BioSciences PCRX Stock Holding History

Persistent Asset Partners’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,962	Closed	-$335K	–	440
2025 Q4	$335K	Sell	12,962 -613	-5%	-$14.6K	0.15%	172
2025 Q3	$350K	Hold	13,575	–	–	0.24%	99
2025 Q2	$324K	Buy	13,575 +4,612	+51%	+$116K	0.24%	94
2025 Q1	$223K	Buy	+8,963	New	+$215K	0.19%	96

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Persistent Asset Partners's PCRX Position: Q1 2026 in Review

Persistent Asset Partners sold out of Pacira BioSciences (PCRX) in Q1 2026, closing a stake of 12,962 shares — an estimated $335K sold.

Persistent Asset Partners first reported a position in PCRX in Q1 2025 and held it in 4 quarters. The position peaked at $350K in Q3 2025. 242 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Persistent Asset Partners reported no remaining Pacira BioSciences position as of Q1 2026 after selling out during the quarter.
Persistent Asset Partners sold 12,962 Pacira BioSciences shares in Q1 2026, an estimated $335K.
Persistent Asset Partners first reported a position in Pacira BioSciences in Q1 2025 and held it in 4 quarters.
Persistent Asset Partners's Pacira BioSciences position peaked at $350K in Q3 2025.
242 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.